Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930544 | 1.00 | KMT2A (0.36) | KMT2AGAARAD52MEN1SIGMAR1 | |
| SCHEMBL31441143 | 1.00 | KMT2A (0.36) | KMT2AGAARAD52MEN1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1828960 | 0.98 | OPRM1 (0.35) | KMT2AGAARAD52MEN1SIGMAR1 | |
| SCHEMBL25165704 | 0.97 | KMT2A (0.37) | KMT2AGAARAD52MEN1SIGMAR1 | |
| SCHEMBL8265735 | 0.97 | KMT2A (0.37) | KMT2AGAARAD52MEN1SIGMAR1 | |
| SCHEMBL16757065 | 0.95 | KMT2A (0.36) | KMT2AGAARAD52MEN1SIGMAR1 | |
| SCHEMBL470816 | 0.95 | KMT2A (0.36) | KMT2AGAARAD52MEN1SIGMAR1 | |
| SCHEMBL4590548 | 0.90 | GAA (0.38) | KMT2AGAARAD52KCNH2 | |
| SCHEMBL30699749 | 0.87 | GAA (0.37) | KMT2AGAARAD52 | |
| SCHEMBL16143384 | 0.82 | GAA (0.50) | KMT2AGAARAD52SIGMAR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297693-B2 | Nitrogen-containing heterocyclic compounds and their use as Raf inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-11-20 | — | — | US | claimed |
| EP-1432702-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS RAF INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-16 | — | — | EP | claimed |
| US-20040209883-A1 | Nitrogen-containing heterocyclic compounds and their use as raf inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-21 | — | — | US | claimed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| US-8354406-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-15 | — | — | US | disclosed |
| CN-101247804-B | chemical compound | SMITHKLINE BEECHAM CORP | 2012-09-26 | — | — | CN | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2011123937-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| CN-101247804-A | chemical compound | SMITHKLINE BEECHAM CORP (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| US-7297693-B2 | Nitrogen-containing heterocyclic compounds and their use as Raf inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-11-20 | — | — | US | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1432702-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS RAF INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | KMT2A 629/4885GAA 4581/4885RAD52 3370/4885 |
| US-20040209883-A1 | Nitrogen-containing heterocyclic compounds and their use as raf inhibitors | BRAF, RAF1, NPR1 | KMT2A 3248/4885GAA 4458/4885RAD52 2855/4885 |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | KMT2A 1936/4885GAA 2863/4885RAD52 1923/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | KMT2A 629/4885GAA 4581/4885RAD52 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.